EP
CATX icon

Essential Partners’s Perspective Therapeutics CATX Stock Holding History

Essential Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20 Buy
6
+1
+20% +$4 ﹤0.01% 2829
2026
Q1 		$21 Buy
+5
New +$21 ﹤0.01% 2821

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Essential Partners's CATX Position: Q2 2026 in Review

Essential Partners increased its Perspective Therapeutics (CATX) stake by 20% in Q2 2026, buying an estimated $4 and bringing the position to 6 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Essential Partners first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $21 in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Essential Partners held 6 shares of Perspective Therapeutics worth $20 as of Q2 2026.
  • Essential Partners bought 1 Perspective Therapeutics share in Q2 2026, an estimated $4.
  • Perspective Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2829 holding.
  • Essential Partners first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Perspective Therapeutics position peaked at $21 in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.